Altitude Acquisition — SPAC Merger (September 2023)
26 slides from Altitude Acquisition's SPAC merger presentation, Sep 20, 2023
Slide 1: SynCardia Total Artificial Heart: The gift of time
SynCardia (“TAH”) Total Artificial Heart The gift of time Saving one life at a time
Slide 2: Disclaimer
THIS PRESENTATION (TOGETHER WITH ORAL STATEMENTS MADE IN CONNECTION HEREWITH, (THIS “PRESENTATION”) IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. THIS PRESENTATION HAS NOT BEEN APPROVED BY ANY REGULATORY AUTHORITY. THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE, OR ANY SOLIC
Slide 3: Industry and Market Data; Trademarks; Additional Information
Industry and Market Data In this Presentation, we rely on and refer to information and statistics regarding market participants in the sectors in which the Company competes and other industry data. We obtained this information and statistics from third-party sources, including reports by market rese
Slide 4: Financial Projections
Financial Projections This Presentation contains certain financial projections. These financial projections are for illustrative purposes only and relate to future performance and reflect the Company’s views as of the date of this Presentation. The financial projections are subject to known and unkn
Slide 5: Risk Factors
The risks presented below are certain of the general risks related to the Company, SynCardia, Altitude, and the proposed business combination among the Company, Altitude and their respective subsidiaries, as applicable (the “Business Combination”), and such list is not exhaustive. You should careful
Slide 6: Risks Related to Our Business (Continued)
Risks Related to Our Business (Continued) We are subject to credit risk from our accounts receivable related to its product sales, which include sales within foreign countries that have recently experienced economic turmoil. We are subject to risks associated with currency fluctuations, and changes
Slide 7: Risks Related to Intellectual Property
Risks Related to Intellectual Property Many aspects of the SynCardia TAH are no longer protected by patents, and we may be unable to protect our products from competition through other means. The medical device industry is characterized by extensive patent litigation, and we could become subject to
Slide 8: Risks Related to the Combined Company's Securities
Risks Related the Combined Company’s Securities Following Consummation of the Business Combination The requirements of being a public company may strain our resources, divert management’s attention, and affect our ability to attract and retain executive management and qualified board members. If, fo
Slide 9: SynCardia Total Artificial Heart (TAH)
SynCardia Total Artificial Heart (“TAH”) Replaces full functions of a failing human heart, for patients with end-stage biventricular failure Addresses $30B TAM and $5B SAM FDA PMA as a Bridge-to-Transplant (“BTT”) Plan to return to Europe under CE MDR in early 2024 Strong clinical track record - 2,0
Slide 10: Cardiovascular Diseases are the Leading Cause of Death Globally
Cardiovascular Diseases are the Leading Cause of Death Globally Source: WHO, European Journal of Heart Failure, American Heart Association, U.S. CDC, L.E.K. Research and Analysis Notes: 1. No. of deaths related to heart failure in 2018, recorded on death certificates 2. Total medical costs relating
Slide 11: Substantial Demand-Supply Imbalance Driving Urgent Need for TAH
Substantial Demand-Supply Imbalance Driving Urgent Need for TAH Source: Current Opinion in Cardiology, United Network for Organ Sharing, Current Opinion in Cardiology, CDC, L.E.K. Research and Analysis 1 Date period: 2010 to 2020 2 Could be as high as 75% end-stage heart failures 5% are end-stage he
Slide 12: Implant
Implant Simple design – 13 components, no electronics Ventricles – Proprietary Segmented Polyurethane (SPUS) with Dacron™ Mesh. Unique geometry to minimize hemolysis Precisely angled tilting disc in SynHall valves designed to “wash” blood vessels Diaphragm - Four layers of SPUS separates blood from
Slide 13: External Drivers
Freedom Home Discharge Driver Portable Patient-proof portable driver in backpack on pull-cart Rechargeable Li-ion batteries C2 Hospital Driver Delivers pneumatic pulsatile air to drive flow flow through diaphragms Monitors patient condition without sensors or electrical connections inside patient Dy
Slide 14: Established usage
om Established usage IMPLANT SIZES NOGhp 1897 | roc ran = 103 | 50cc TAH+t REGION OF IMPLANTS se 1026 US&Canada France 447 N @ 974 Germany 362 Intemational ayy 47 Australia 8 Others 110 1,945 13% A Female ot 4 Osuncardia A Pleard Medical Compan
Slide 15: Strong Clinical Results and Proven Efficacy
Strong Clinical Results and Proven Efficacy Source: The New England Journal of Medicine, SynCardia 79% Survival rate to transplantation (vs. 46% in control group) 70% Survival rate at 1-year (vs. 31% in control group) Over 60% Patients survived over 2 years or successfully transplanted 6 years 9 mon
Slide 16: Survivability comparable to direct HTx
Survivability comparable to direct HTx SynCardia Total Artificial Heart (TAH) Experience1 45% INTERMACS 1 37% INTERMACS 2 46.1 ± 2.3 Mean Age (24-63) 44% Dilated Cardiomyopathy 42% Ischemic Cardiomyopathy 5% Myocarditis 5% Post - Cardiotomy 73 consecutive patients 50 patients transplanted post TAH 1
Slide 17: A true solution for chronic heart failure
A true solution for chronic heart failure All other interventions designed only to slow progression of heart failure, not cure it TAH patients don’t die of heart failure but of other organ failures TAH patients require less medication than LVAD or HTx patients Duration on Device - World record: 6.75
Slide 18: Amazing patients enjoying a high quality of life
Amazing patients enjoying a high quality of life Source: SynCardia Mohamad, 27, the first TAH transplant in Lebanon Chris, 51, hiked a total of 607 miles after TAH transplantation Stan, 23, played basketball wearing Freedom® Portable Driver in the backpack Randy, 39, completed the 4.2-mile Pat’s Run
Slide 19: Regulatory & Reimbursement
Regulatory & Reimbursement Regulatory Status US FDA: Approved as BTT, applying for LT indication Europe: Not currently approved for use in the EU : Withdrew from CE MDD, file for CE MDR by year-end Others: Compassionate, Emergency Use Authorizations or Special Dispensations Reimbursement US CMS: DRG
Slide 20: New Products Pipeline
New Products Pipeline Freedom Driver (UPGRADE) – 2023-2024 More accurate fill volume measurements Quieter: 65 to ~ 55 dB Extend maintenance cycle from 60-90 days to 1-year Ability to measure RAP, PAP, LAP & AP (SYS/DIA) Reduce false alarm rate by 50% Freedom II Driver (NEW) – 2025 Design freeze by y
Slide 21: SynCardia Seeking FDA approval for Long-Term Indication
SynCardia Seeking FDA approval for Long-Term Indication Based on past FDA approvals, we believe the criteria for long-term indication is for a patient to: Survive over 2 years; or Getting transplanted Long-term Indication Approval Left ventricular heart assist devices (LVAD) underwent similar applic
Slide 22: Significant Progress in Global Market Expansion
Significant Progress in Global Market Expansion Seeking local partner in India and initiated regulatory registration process in 2022 Completing training programs with several transplant hospitals and preparing for first heart transplant in 2023 CHINA MIDDLE EAST SOUTHEAST ASIA Working towards obtain
Slide 23: Global Expansion
Global Expansion Historical market presence Initial expansion target markets Secondary expansion target markets JAPAN Population: 126M Heart failures: 979K1 CHINA Population: 1,412M Heart failures: 4.5M2 SOUTHEAST ASIA Population: 685M Heart failures: 9M3 MIDDLE EAST Population: 578M Heart failures:
Slide 24: SynCardia is Far Ahead of Competition
SynCardia is Far Ahead of Competition… Company Status Approval obtained US EU ROW Blood volume Device size No. of implants Cost per TAH ASP Bio-compatible materials Implant Weight The Only TAH approved for Commercial use by US FDA, Health Canada and European CE Obtained CE Marking for Commercial Use
Slide 25: Picard Management and Board Members
Picard Management and Board Members Richard Fang, PhD Board Member ‘+ Managing Partner of Hunniwell Lake Ventures Former CEO of Reach Surgical ‘© R&D Engineer ~ Johnson & Johnson Ethicon Ph.0, Physics, Purdue Univer + MBA, University of Cincinnati Os Daniel Teo Board Member ‘© Managing Partner of Hu
Slide 26: Summary
Summary The only commercially-available Total Artificial Heart First and the only TAH option in the U.S. Approved by U.S. FDA, Europe CE and Canada Health Strong track record of developing products with dominant market positioning Achieved favorable clinical data with 79% survival rate to transplant